文献速递糖尿病

胰岛素泵使用与1型糖尿病成人住院结局:2022年全国再入院数据库分析

Insulin pump use and hospital outcomes in adults with type 1 diabetes: a 2022 Nationwide Readmissions Database analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

CONTEXT: Adults with type 1 diabetes (T1D) experience substantial inpatient morbidity, including frequent readmissions and measurable in-hospital mortality, contributing significantly to US health care utilization.…

要点

  • 胰岛素泵治疗与1型糖尿病成人30天再入院风险降低独立相关。
  • 泵治疗组住院期间死亡率0.90%,低于注射组1.31%。
  • 泵治疗与90天再入院风险降低的关联持续存在。

核心结论

  • 在具有全国代表性的队列中,胰岛素泵治疗与1型糖尿病成人30天再入院和住院期间死亡率降低独立相关。

研究设计与样本

  • 回顾性队列研究,使用2022年全国再入院数据库(全国代表性全付款方住院数据库)。
  • 纳入成人(≥18岁)1型糖尿病住院患者,以ICD-10-CM编码识别。

主要发现

  • 泵使用者30天再入院率为14.64%,单纯注射组为20.63%。
  • 索引住院期间住院死亡率:泵使用者0.90%(95%CI 0.78-1.05),单纯注射组1.31%(95%CI 1.21-1.42)。
  • 次要分析中,泵治疗与90天再入院风险降低的关联持续存在。

临床怎么用

  • 对于住院的1型糖尿病成人,胰岛素泵治疗可能与较低的30天再入院和住院死亡风险相关,临床决策时可综合考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adults with type 1 diabetes (T1D) experience substantial inpatient morbidity, including frequent readmissions and measurable in-hospital mortality, contributing significantly to US health care utilization. OBJECTIVE: To evaluate the association between insulin delivery modality and 30-day readmission and in-hospital mortality among adults hospitalized with T1D. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using the 2022 Nationwide Readmissions Database, a nationally representative all-payer inpatient database. Adults (≥18 years) hospitalized with T1D were identified using ICD-10-CM codes. Index admissions were defined as the first eligible hospitalization per patient within the calendar year; December and elective admissions were excluded to ensure complete 30-day follow-up. EXPOSURE: Insulin pump therapy (± injectable insulin) vs injectable insulin only. MAIN OUTCOMES AND MEASURES: Primary outcome was time to first all-cause readmission within 30 days. Secondary outcomes included in-hospital mortality during index admission and readmission. Survey-weighted Cox and logistic regression models estimated adjusted hazard ratios (aHRs) and odds ratios (aORs). RESULTS: The weighted cohort included 230 958 adult index admissions. Thirty-day readmission occurred in 14.64% of pump users vs 20.63% of injectable-only users. After multivariable adjustment, pump therapy was associated with lower readmission risk (aHR, 0.77; 95% CI, 0.74-0.81; P < .001). In secondary analyses, this association persisted for 90-day readmission outcomes. In-hospital mortality during index admission was lower among pump users (0.90% [95% CI, 0.78-1.05]) compared with injectable-only users (1.31% [95% CI, 1.21-1.42]). Pump therapy remained associated with reduced mortality (aOR, 0.78; 95% CI, 0.66-0.93; P = .006). CONCLUSION: In this nationally representative cohort, insulin pump therapy was independently associated with lower 30-day readmission and in-hospital mortality among adults with T1D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Reguram R, Shah R, Vora T, et al. Insulin pump use and hospital outcomes in adults with type 1 diabetes: a 2022 Nationwide Readmissions Database analysis. J Clin Endocrinol Metab. 2026. PMID: 42530032. doi:10.1210/clinem/dgag307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。